FOXL2 Antibody

• Catalog Number: orb1672115
• Category: Antibodies
• Description: FOXL2 Antibody
• Clonality: Recombinant
• Clone Number: WO2
• Tested applications: ELISA, IHC-P, WB
• Reactivity: Human
• Isotype: IgG2a kappa
• Immunogen: Synthetic peptides, corresponding to amino acids 1-42 of human beta amyloid, conjugated to KLH.
• Concentration: batch dependent
• Conjugation: Unconjugated
• Target: FOXL2
• UniProt ID: P05067
• Storage: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
• Buffer/Preservatives: PBS with 0.02% Proclin 300.
• Alternative names: Abeta
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Comparison of recombinant WO2 anti-Amyloid beta (orb1672115) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing Antibody’s recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed- by this method- comparative purity. Subsequently- the specificity of the antibodies was tested in assays detecting immobilised peptides (see B)- in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity- however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.

Comparison of recombinant WO2 anti-Amyloid beta (orb1672115) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing Antibody’s recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed- by this method- comparative purity. Subsequently- the specificity of the antibodies was tested in assays detecting immobilised peptides (see B)- in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity- however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.

Comparison of recombinant WO2 anti-Amyloid beta (orb1672115) with hybridoma-derived WO2 from Competitor M. Panel A shows a Coomassie Blue-stained SDS-PAGE gel comparing Antibody’s recombinant WO2 with antibody from the corresponding hybridoma under native and reducing (DTT) conditions. Both preparations showed- by this method- comparative purity. Subsequently- the specificity of the antibodies was tested in assays detecting immobilised peptides (see B)- in particular various Amyloid-beta derived peptides probed with WO2 (50 ng/ml) and a goat-anti-mouse peroxidase conjugated tracer as shown in C. The recombinant and hybridoma-derived antibody showed comparative selectivity- however higher signal intensity. Titration of recombinant and hybridoma derived WO2 against Aß 2-42 (D)and Aß 3-42(E) indicates that the recombinant antibody has higher activity than the hybridoma-derived counterpart.